Illum L
DanBioSyst UK Ltd, Albert Einstein Centre, Nottingham, UK.
Pharm Res. 1998 Sep;15(9):1326-31. doi: 10.1023/a:1011929016601.
Chitosan has been investigated as an excipient in the pharmaceutical industry, to be used in direct tablet compression, as a tablet disintegrant, for the production of controlled release solid dosage forms or for the improvement of drug dissolution. Chitosan has, compared to traditional excipients, been shown to have superior characteristics and especially flexibility in its use. Furthermore, chitosan has been used for production of controlled release implant systems for delivery of hormones over extended periods of time. Lately, the transmucosal absorption promoting characteristics of chitosan has been exploited especially for nasal and oral delivery of polar drugs to include peptides and proteins and for vaccine delivery. These properties, together with the very safe toxicity profile, makes chitosan an exciting and promising excipient for the pharmaceutical industry for present and future applications.
壳聚糖已作为辅料在制药行业中进行了研究,用于直接压片、作为片剂崩解剂、生产控释固体剂型或改善药物溶解。与传统辅料相比,壳聚糖已显示出具有优越的特性,尤其是在使用上具有灵活性。此外,壳聚糖已用于生产控释植入系统,以长时间递送激素。最近,壳聚糖促进透粘膜吸收的特性尤其被用于极性药物(包括肽和蛋白质)的鼻腔和口服递送以及疫苗递送。这些特性,再加上非常安全的毒性特征,使壳聚糖成为制药行业目前和未来应用中令人兴奋且有前景的辅料。